DK0954588T3 - OB fusionsprotein-sammensætninger og fremgangsmåder - Google Patents

OB fusionsprotein-sammensætninger og fremgangsmåder

Info

Publication number
DK0954588T3
DK0954588T3 DK97952464T DK97952464T DK0954588T3 DK 0954588 T3 DK0954588 T3 DK 0954588T3 DK 97952464 T DK97952464 T DK 97952464T DK 97952464 T DK97952464 T DK 97952464T DK 0954588 T3 DK0954588 T3 DK 0954588T3
Authority
DK
Denmark
Prior art keywords
methods
fusion protein
protein compositions
compositions
fusion
Prior art date
Application number
DK97952464T
Other languages
English (en)
Inventor
Michael Benjamin Mann
Randy Ira Hecht
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0954588T3 publication Critical patent/DK0954588T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
DK97952464T 1996-12-20 1997-12-11 OB fusionsprotein-sammensætninger og fremgangsmåder DK0954588T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77097396A 1996-12-20 1996-12-20
PCT/US1997/023183 WO1998028427A1 (en) 1996-12-20 1997-12-11 Ob fusion protein compositions and methods

Publications (1)

Publication Number Publication Date
DK0954588T3 true DK0954588T3 (da) 2007-05-14

Family

ID=25090296

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97952464T DK0954588T3 (da) 1996-12-20 1997-12-11 OB fusionsprotein-sammensætninger og fremgangsmåder

Country Status (26)

Country Link
EP (2) EP0954588B1 (da)
JP (2) JP4175668B2 (da)
KR (1) KR100937550B1 (da)
CN (1) CN1195858C (da)
AR (2) AR009436A1 (da)
AT (1) ATE351910T1 (da)
AU (1) AU5606098A (da)
BG (1) BG64288B1 (da)
BR (1) BR9713755A (da)
CA (1) CA2275183A1 (da)
CZ (1) CZ298203B6 (da)
DE (1) DE69737266T2 (da)
DK (1) DK0954588T3 (da)
EA (2) EA004791B1 (da)
ES (1) ES2280083T3 (da)
HK (1) HK1021388A1 (da)
HU (1) HU227088B1 (da)
IL (1) IL130396A (da)
NO (2) NO324506B1 (da)
NZ (1) NZ514145A (da)
PL (1) PL194159B1 (da)
PT (1) PT954588E (da)
RS (1) RS49927B (da)
SK (1) SK287578B6 (da)
WO (1) WO1998028427A1 (da)
ZA (1) ZA9711239B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
JP4086908B2 (ja) * 1997-04-17 2008-05-14 アムジエン・インコーポレーテツド 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
TWI257394B (en) 1998-10-23 2006-07-01 Kirin Amgen Inc Thrombopoietic compounds
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20020168363A1 (en) * 2000-04-21 2002-11-14 Amgen Inc. Integrin/adhesion antagonists
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
HUP0303199A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
DK2219031T3 (da) 2001-10-22 2013-06-17 Amgen Inc Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
EP2335715A3 (en) 2004-02-11 2013-12-18 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
CA2575607C (en) 2004-08-03 2017-07-11 Innate Pharma Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1941043B1 (en) 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Method for the recombinant expression of a polypeptide
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
HUE061647T2 (hu) 2011-10-05 2023-08-28 Oned Mat Inc Szilicium nanoszerkezetû aktív anyagok lítium-ion akkumulátorokhoz, és a hozzájuk kapcsolódó eljárások, összetevõk, alkatrészek és eszközök
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
RS64850B1 (sr) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Metodi za detektovanje neutrališućih antitela na leptin
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) * 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
CA2238307A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life

Also Published As

Publication number Publication date
KR20000069617A (ko) 2000-11-25
SK287578B6 (sk) 2011-03-04
PT954588E (pt) 2007-03-30
EP0954588A1 (en) 1999-11-10
HUP0000302A3 (en) 2005-12-28
CA2275183A1 (en) 1998-07-02
NO992779L (no) 1999-08-19
BR9713755A (pt) 2000-02-01
JP4659068B2 (ja) 2011-03-30
NO325096B1 (no) 2008-02-04
AR059907A2 (es) 2008-05-07
NO992779D0 (no) 1999-06-08
JP2001512417A (ja) 2001-08-21
BG64288B1 (bg) 2004-08-31
CZ9902036A3 (cs) 2000-10-11
JP2008289487A (ja) 2008-12-04
PL194159B1 (pl) 2007-05-31
HUP0000302A2 (hu) 2000-06-28
KR100937550B1 (ko) 2010-01-19
NO20071415L (no) 1999-08-19
AU5606098A (en) 1998-07-17
EA004791B1 (ru) 2004-08-26
IL130396A0 (en) 2000-06-01
ES2280083T3 (es) 2007-09-01
EA200100216A1 (ru) 2001-08-27
SK77499A3 (en) 2001-04-09
YU27999A (sh) 2000-10-30
EP1835030A1 (en) 2007-09-19
CZ298203B6 (cs) 2007-07-18
AR009436A1 (es) 2000-04-12
ATE351910T1 (de) 2007-02-15
PL334242A1 (en) 2000-02-14
EA199900575A1 (ru) 2000-02-28
HK1021388A1 (en) 2000-06-09
HU227088B1 (en) 2010-06-28
JP4175668B2 (ja) 2008-11-05
NZ514145A (en) 2003-08-29
CN1195858C (zh) 2005-04-06
RS49927B (sr) 2008-09-29
CN1246154A (zh) 2000-03-01
EP0954588B1 (en) 2007-01-17
DE69737266T2 (de) 2007-11-08
EA004790B1 (ru) 2004-08-26
ZA9711239B (en) 1998-06-23
DE69737266D1 (de) 2007-03-08
IL130396A (en) 2011-09-27
BG103522A (en) 2000-03-31
WO1998028427A1 (en) 1998-07-02
NO324506B1 (no) 2007-11-05

Similar Documents

Publication Publication Date Title
DK0954588T3 (da) OB fusionsprotein-sammensætninger og fremgangsmåder
NO991676L (no) FremgangsmÕter og sammensetninger for immunmodulering
NO973046D0 (no) Elastiske sementsammensetninger og fremgangsmåte
NO973048D0 (no) Elastiske sementsammensetninger og fremgangsmåter
NO20000700D0 (no) Interleukin-18-proteiner samt fremstilling og anvendelse derav
IS4496A (is) Úðablöndur úr peptíðum og próteinum
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
ZA964733B (en) Ob protein compositions and methods
DK0915880T3 (da) Azolotriaziner og pyrimidiner
BR9709529A (pt) Fragmentos de leptina (proteína ob)
DK0804078T3 (da) Sammensætning og anvendelse deraf
NO985385L (no) Bitumensammensetninger og fremgangsmÕte for fremstilling derav
NO985806L (no) Kitinasematerialer og fremgangsmÕter
NO995062D0 (no) <Beta>-anyloidpeptid-bindende proteiner og polynuldeotider som kodes for samme
NO971505D0 (no) Trofinin og trofininhjelperproteiner
HUP0000280A3 (en) Canine ob protein compositions and methods
TR199701666A3 (tr) Sismanliga karsi proteinler
NO973047D0 (no) Elastiske sementsammensetninger og fremgangsmåter
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
NO983556L (no) Formulering og anvendelse
DE59704868D1 (de) Gelenk
NO952766D0 (no) Opplösningsmiddelsammensetninger og metoder
SE9602287D0 (sv) Novel protein and methods for its use
SE9701041D0 (sv) Novel proteins and their use
IS8568A (is) Vatnsfælanlega umbreyttar prótínsamsetningar og aðferðir